Aromatase and its inhibitors

Journal of Steroid Biochemistry and Molecular Biology

Volumn 69, Issue 1-6, 1999, Pages 205-210

  Brodie, Angela ^a   Lu, Qing ^a   Long, Brian ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

BREAST CANCER; CONFERENCE PAPER; DRUG EFFECT; ENZYME ACTIVITY; ESTROGEN BLOOD LEVEL; HUMAN; IN SITU HYBRIDIZATION; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; TUMOR GROWTH;

ANIMALS; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; ENZYME INHIBITORS; HUMANS;

EID: 0032977449     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(99)00051-5     Document Type: Conference Paper

References (43)

1. McGuire W.L. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. Iacobelli S., King R.J.B., Lidner H.R., Lippman M.E. Hormones and Cancer. vol. 15:1980;337-344 Raven Press, New York.
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. The Lancet. 339:1992;1-15.
3. Clarke R., Lippman M.E. Antiestrogens resistance: mechanisms and reversal. Teicher B.A. Drug Resistance in Oncology. 1992;501-536 Marcel Dekker Inc, New York.
4. Schwarzel W.C., Kruggel W., Brodie H.J. Studies on the mechanism of estrogen biosynthesis - VII: the development of inhibitors of the enzyme system in human placenta. Endocrinology. 92:1973;866-880.
5. Brodie A.M.H., Schwarzel W.C., Shaikh A.A., Brodie H.J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen dependent processes in reproduction and breast cancer. Endocrinology. 100:1977;1684-1694.
6. Cole P.A., Robinson C.H. Mechanism and inhibition of cytochrome P-450 aromatase. J. Med. Chem. 33:1990;2933-2944.
7. Akhtar M., Njar V.C.O., Wright J.N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J. Steroid Biochem. Mol. Biol. 44:1993;375-387.
8. Corbin C.J., Graham-Lorence S., McPhaul M., Mason J.I., Mendelson C.R., Simpson E.R. Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in non-steroidogenic cells. Proc. Acad. Sci. USA. 85:1988;8948-8953.
9. Nebert D.W., Nelson D.R., Coon M.J., Estabrook R.W., Feyereisen R., Fujii-Kuriyama Y., Gonzalez F.J., Guengerich F.P., Gunsalas I.C., Johnson E.F., Loper J.C., Sato R., Waterman M.R., Waxman D.J. The P-450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Mol. Biol. 10:1991;1-14.
10. Marsh D.A., Romanoff L.P., Williams K.I.H., Brodie A.M.H. Synthesis of deuterium and tritium labeled 4-hydroxy-androstenedione, an aromatase inhibitor, and its metabolism in vitro. Biochem. Pharm. 31:1982;701-705.
11. Brueggermeier R.W., Li P-K., Snider C.E., Darby M.V., Katlic N.E. 7α-Substituted androstenediones as effective in vitro and in vivo inhibitors of aromatase. Steroids. 50:1987;163-178.
12. Metcalf B.W., Wright C.L., Burkhart J.P., Johnston J.O. Substrate-induced inactivation of aromatase by allenic and acetylenic steroids. J. Amer. Chem. Soc. 103:1981;3221-3222.
13. Plourde P.V., Dyroff M., Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res. Treat. 30:1994;103-111.
14. Bhatnagar A.S., Hausler A., Trunet P., Schieweck K., Lang M., Bowman P. Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 37:1990;1021-1027.
15. Brodie A.M.H., Longcope C. Inhibition of peripheral aromatization by aromatase inhibitors, 4-hydroxy-and 4-acetoxy-androstene-3,17-dione. Clin. Endocrin. 106:1980;19-21.
16. Brodie A.M.H., Romanoff L.P., Williams K.I.H. Metabolism of the aromatase inhibitor 4-hydroxyandrost-4-ene-3,17-dione by male rhesus monkeys. J. Steroid Biochem. 14:1981;693-696.
17. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Tsai-Morris C.H. Effects of 4-hydroxyandrostenedione and other compounds in the DMBA breast carcinoma model. Cancer Res. 42:1982;3360s-3364s.
18. Wing L.Y., Garrett W.M., Brodie A.M.H. The effect of aromatase inhibitors, aminogluthimide and 4-hydroxyandrostenedione in cyclic rats with DMBA-induced mammary tumors. Cancer Res. 45:1985;2425-2428.
19. Brodie A.M.H., Garrett W.M., Hendrickson J.R., Marcotte P.A., Robinson C.H. Inactivation of aromatase activity in placental and ovarian microsomes by 4-hydroxyandrostene-3,17-dione and 4-acetoxyandrostene-3,17-dione. Steroids. 38:1981;693-702.
20. Coombes R.C., Goss P., Dowsett M., Gazet J.C., Brodie A.M.H. 4-Hydroxyandrostenedione treatment of postmenopausal patients with advanced breast cancer. The Lancet. 2:1984;1237-1239.
21. Goss P.E., Coombes R.L., Powles T.J., Brodie A.M.H. Treatment of advanced postmenopausal breast cancer with aromatase inhibitor, 4-hydroxyandrostenedione-Phase 2 report. Cancer Res. 46:1986;4823-4826.
22. Dowsett D.M., Coombes R.C. Second generation aromatase inhibitor - 4-OHA. Breast Cancer Res. Treat. 30:1994;81-87.
23. Possinger K., Jonat W., Hoffken K. Formestane in the treatment of advanced postmenopausal breast cancer. Ann. Oncol. 5:1994;S7-S10.
24. Bajetta E., Zilemba N., Norersco C., Bichisoa E. Formestane: effective therapy in postmenopausal women with advanced breast cancer. Nagel G., Possinger K. Selective Aromatase Inhibitors - Improved Quality of Life for Metastatic Breast Cancer Patients, Excerpta Oncol. Ciba. 1996;51-56 Ciba-Geigy Verlag, Wehr/Barden.
25. Cunningham D., Powles T.J., Dowsett M., Hutchinson G., Brodie A.M.H., Ford H.T., Gazet J.C., Coomes R.C. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother. Pharmacol. 20:1987;253-255.
26. Buzdar A., Jonat W., Howell A., Jones S.E., Blomqvist C., Vogel C.L., Eiermann W., Wolter J.M., Azab M., Webster A., Plourde P.V. Anastrozole (ARIMIDEX), a potent and selective aromatase inhibitor vs megesterol acetate (MEGACE) in postmenopausal women with advanced breast cancer: results of an overview analysis of two phase III trials. J. Clin. Oncol. 14:1996;2000-2011.
27. Jonat W., Howell A., Blomqvist C., Eiermann W., Winalad G., Tyrrell C., Mauriac H.R., Lundgren S., Hellmund R., Azab M. A randomized trial comparing two doses of the new selective aromatase inhibitor anastrozole ('ARIMIDEX') with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur. J. Cancer. 32A:1996;404-412.
28. Buzdar A, Jonat W, Howell A, Yin H, Lee D Significant improved survival with Arimidex (anastrozole) vs megestrol acetate in postmenopausal advanced breast cancer: updated results of two randomized trials. In: Proceedings of American Society of Clinical Oncology, 1997. 16. p. 156a. The Arimidex International Study Group, Houston, TX, Kiel, Germany, Manchester, UK, Wilmington, DE, Macclesfield, UK, (Arimidex is a trademark, property of Zeneca Limited).
29. Iverson T.J., Smith I.E., Ahern J., Smithers D.A., Trunet P.F., Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J. Clin. Endocr. Metab. 77:1993;324-331.
30. Smith I.E. Letrozole: creating a new standard. Advanced Breast Cancer: Reassessing Hormonal Therapy-Ciba International Symposium Series. vol. 2:1996;45-55 The Parthenon Publishing Group, New York.
31. Bisagni C., Cocconi G., Ceri C., et al. CGS 20267: a new oral aromatase inhibitor: phase I study in postmenopausal advanced breast cancer patients. Proc. Am. Soc. Clin. Oncol. 12:1993;80.
32. Szyczak J., Milewicz A., Thijssen J.H.H., Blankenstein M.A., Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. Steroids. 63:1998;319-321.
33. van Landegham A.A.J., Portman J., Nabauurs M. Endogenous concentration and subcellular distribution of estrogens in normal and maligant human breast tissue. Cancer Res. 45:1985;2900-2906.
34. Blankenstein M.A., van de Ven J., de Jong P.C., Thijssen J.H.H. Intratumoral levels of estrogens in breast cancer. Xth International Congress on Hormonal Steroids, Quebec City, Canada. 1998.
35. Lu Q., Nakmura J., Savinov A., Yue W., Weisz J., Dabbs D.J., Wolz G.A. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology. 137:1996;3061-3068.
36. Reed M.J., Aherne G.W., Ghilchick M.W., Patel S., Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int. J. Cancer. 49:1991;562-565.
37. Yue W., Zhou D., Chen S., Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 54:1994;5092-5095.
38. Yue W., Wang J., Savinov A., Brodie A. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res. 55:1995;3073-3077.
39. Yue W., Wang J., Hamilton C.J., et al. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 58:1998;927-932.
40. Q. Lu, W. Yue, J. Wang, Y. Lui, B. Long, A. Brodie, The effects of aromatase inhibitors and antiestrogens in the nude mouse model, Breast Cancer Res. Treat. 50 (1999) 63-71.
41. Brodie A., Lu Q., Liu Y., Long B., Wang J-P., Yue W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology. 12:1998;29-33.
42. Jordan V.C., Rowsby L., Dix C.J., Prestwich G. Dose-related effects of non-steroidal antiestrogens and estrogens on the measurement of cytoplasmic estrogen receptors in the rat and mouse uterus. J. Endocrinol. 78:1978;71-78.
43. Q. Lu, Y. Liu, B.J. Long, D. Grigoryev, M. Gimbel, A. Brodie, The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer, Breast Cancer Res. Treat. In press.